AMMIVO DIN 02571595
Health Canada record
| Active ingredient(s) | SODIUM PHENYLACETATE 100 MG; SODIUM BENZOATE 100 MG |
|---|---|
| Dosage form | Solution |
| Route | Intravenous |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | A16AX30 SODIUM BENZOATE AND SODIUM PHENYLACETATE |
| Original market date | |
| Current status date | 16-Sep-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Sterimax Inc — licence 100925, currently licensed, last inspection rating C (2024-05-13).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 38296 | 2026-09-16 | New Drug Submission (NDS) |
International API supply for SODIUM PHENYLACETATE
2 active FDA Drug Master Files.
Special Access Programme
This molecule appears on Health Canada's list of drugs most often requested through the Special Access Programme.
Request a quote for AMMIVO